ACLX Key Statistics, Chart & Performance
The current stock price of ACLX is 74.96 USD. In the past month the price decreased by -13.54%. In the past year, price decreased by -14.89%.
ACLX Latest News, Press Relases and Analysis
ACLX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.29 | 405.44B | ||
| AMGN | AMGEN INC | 15.29 | 179.97B | ||
| GILD | GILEAD SCIENCES INC | 15.3 | 155.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.42 | 108.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.92 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.43 | 56.92B | ||
| INSM | INSMED INC | N/A | 43.74B | ||
| NTRA | NATERA INC | N/A | 32.75B | ||
| BIIB | BIOGEN INC | 10.56 | 25.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.08 | 21.58B | ||
| INCY | INCYTE CORP | 16.55 | 20.75B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.12B |
Related stock screener links
About ACLX
Company Profile
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Company Info
ARCELLX INC
800 Bridge Parkway
Redwood City CALIFORNIA US
Employees: 163
Phone: 12403270603
ARCELLX INC / ACLX FAQ
What does ACLX do?
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Redwood City, California and currently employs 163 full-time employees. The company went IPO on 2022-02-04. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. The company is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Can you provide the latest stock price for ARCELLX INC?
The current stock price of ACLX is 74.96 USD. The price decreased by -16.89% in the last trading session.
Does ACLX stock pay dividends?
ACLX does not pay a dividend.
What is the ChartMill rating of ARCELLX INC stock?
ACLX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ARCELLX INC (ACLX) stock?
25 analysts have analysed ACLX and the average price target is 113.73 USD. This implies a price increase of 51.72% is expected in the next year compared to the current price of 74.96.
What is the Price/Earnings (PE) ratio of ARCELLX INC (ACLX)?
ARCELLX INC (ACLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.93).
When does ARCELLX INC (ACLX) report earnings?
ARCELLX INC (ACLX) will report earnings on 2026-03-17, after the market close.
ACLX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ACLX. When comparing the yearly performance of all stocks, ACLX is a bad performer in the overall market: 61.13% of all stocks are doing better.
ACLX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACLX. ACLX has a great financial health rating, but its profitability evaluates not so good.
ACLX Financial Highlights
Over the last trailing twelve months ACLX reported a non-GAAP Earnings per Share(EPS) of -3.93. The EPS decreased by -453.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.22% | ||
| ROE | -49.44% | ||
| Debt/Equity | 0 |
ACLX Forecast & Estimates
25 analysts have analysed ACLX and the average price target is 113.73 USD. This implies a price increase of 51.72% is expected in the next year compared to the current price of 74.96.
For the next year, analysts expect an EPS growth of -103.72% and a revenue growth -63.77% for ACLX